Elmera Q2 2026 slides: profit jumps 30% as deal review proceeds

Elmera reported Q2 2026 adjusted EBIT of NOK 121m, up 30.1% YoY, alongside adjusted net revenue of NOK 399m (+7.8% YoY) and flat operating expenses (NOK 278m). The company cut net debt to NOK 1.04bn from NOK 1.86bn at March 31, driven by a NOK 988m working-capital release (including a shift from cash collateral to bank guarantees). Simultaneously, Fortum’s recommended NOK 47/share tender offer remains pending regulatory approvals (Norway/Sweden/Finland) and requires at least 90% acceptance, while Elmera reiterated 2026 targets of ~NOK 575m full-year adjusted EBIT and maintained its 80%+ payout ratio policy.

Analysis

This quarter matters less for operating momentum than for what it does to the merger arb math. A cleaner balance sheet and stronger cash conversion reduce the probability that Fortum tries to renegotiate, but they also make a failed deal less damaging because the standalone earnings power is proving more durable than the market likely modeled. In other words, the downside cushion is improving at the same time as the takeout probability rises.

The second-order winner is not just the target; it is any large-scale Nordic utility with low funding costs and access to collateral/guarantee capacity. Smaller retail power players are structurally disadvantaged when switching churn normalizes and working-capital support becomes a competitive weapon, because they cannot tolerate collateral drag as easily as Elmera can now. If the offer stalls, that liquidity advantage should still support the equity versus weaker peers over the next 1-3 months.

Consensus seems to be treating this as a low-volatility cash arb, but the real risk is timing, not price. Regulatory delay or a sub-90% acceptance outcome is the main tail risk over days to weeks; over 6-18 months the bigger question is whether improved run-rate cash flow makes the current offer look too cheap, inviting a superior bid that the market is barely pricing. Absent that, the most likely outcome is a narrow spread that collapses quickly once approvals land.

Key Decisions for Investors

• Long Elmera on any pullback while the offer spread remains above ~2.0-2.5%; target is low-single-digit gross return over 1-3 months if regulatory approvals arrive on schedule.
• Take profits or trim aggressively if Elmera trades above ~46.5 NOK before approval of the offer document; the residual upside is too small relative to acceptance and timing risk.
• If approvals slip beyond the next 4-6 weeks, consider a relative-value trade: long Elmera vs short a Nordic utilities basket to isolate deal-completion optionality from sector beta.
• Treat any superior-bid thesis as an alert, not a base case; only add if another strategic buyer emerges or if the spread widens materially on a 90% acceptance concern.
• No options trade unless implied volatility spikes on a regulatory headline; then prefer short-dated call spreads as a tactical hedge on deal-extension risk, not a core position.